Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29237434 | 0.82 | NR3C1 (0.34) | — | |
| SCHEMBL30967826 | 0.82 | NR3C1 (0.34) | — | |
| SCHEMBL1466626 | 0.81 | NR3C1 (0.36) | ALDH1A1L3MBTL1 | |
| SCHEMBL8869444 | 0.80 | LMNA (0.39) | ALDH1A1 | |
| SCHEMBL7016208 | 0.76 | NR3C1 (0.46) | ALDH1A1 | |
| SCHEMBL1467101 | 0.73 | NPC1 (0.32) | — | |
| SCHEMBL2502244 | 0.67 | KDM4E (0.36) | ALDH1A1 | |
| SCHEMBL29236 | 0.66 | SLC6A2 (0.41) | L3MBTL1 | |
| SCHEMBL30522140 | 0.66 | TSHR (0.47) | ALDH1A1L3MBTL1 | |
| SCHEMBL28715842 | 0.66 | TSHR (0.44) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198274-B2 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100016312-A1 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016312-A1 | Substituted indolyl and indazolyl derivatives and uses thereof | MAOB, MAOA, TPH1 | ALDH1A1 751/4885L3MBTL1 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.